D. Boral Capital Issues Pessimistic Forecast for Pulmonx (NASDAQ:LUNG) Stock Price

Pulmonx (NASDAQ:LUNG) had its target price cut by investment analysts at D. Boral Capital from $16.00 to $14.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities analysts have also recently commented on LUNG. Wells Fargo & Company reduced their target price on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Lake Street Capital reduced their price objective on Pulmonx from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, July 31st. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research note on Wednesday, October 8th. Piper Sandler cut Pulmonx from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $9.00 to $2.50 in a research note on Thursday, July 31st. Finally, Wall Street Zen cut Pulmonx from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.81.

Pulmonx Stock Performance

Pulmonx stock opened at $1.92 on Tuesday. The stock has a market cap of $78.24 million, a P/E ratio of -1.34 and a beta of 0.42. The company has a current ratio of 5.35, a quick ratio of 4.63 and a debt-to-equity ratio of 0.54. The stock has a 50 day moving average of $1.69 and a 200-day moving average of $2.61. Pulmonx has a 52 week low of $1.47 and a 52 week high of $9.37.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $23.86 million during the quarter, compared to analysts’ expectations of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. On average, analysts expect that Pulmonx will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Pulmonx

A number of hedge funds have recently added to or reduced their stakes in LUNG. Corton Capital Inc. bought a new stake in Pulmonx in the second quarter valued at $32,000. SG Americas Securities LLC raised its stake in shares of Pulmonx by 95.8% during the third quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock valued at $40,000 after purchasing an additional 12,166 shares in the last quarter. R Squared Ltd bought a new stake in shares of Pulmonx during the second quarter valued at about $41,000. Bank of Montreal Can bought a new stake in shares of Pulmonx during the second quarter valued at about $53,000. Finally, Vontobel Holding Ltd. bought a new stake in shares of Pulmonx during the first quarter valued at about $82,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.